Organization (Other)
Novartis Vaccines
ClinicalTrials.gov lists Novartis Vaccines as lead sponsor of 165 trials. It has 4 active development programs and 12 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Novartis Vaccines: 165 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Influenza, Human | 91 |
| Meningococcal Infections | 61 |
| Meningitis | 47 |
| Meningitis, Bacterial | 34 |
| Meningitis, Meningococcal | 32 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 16 |
| 2013 | 25 |
| 2012 | 12 |
| 2011 | 23 |
| 2010 | 30 |
| 2009 | 30 |
| 2008 | 25 |
| 2007 | 31 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: none of the 165 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (4)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| MenACWY CRM | Meningococcal Infections | Phase 3 | 14 |
| MenACWY CRM | Meningitis | Phase 3 | 11 |
| Cell culture derived influenza vaccine | Influenza, Human | Phase 3 | 2 |
| Egg-derived influenza virus vaccine | Influenza, Human | Phase 3 | 1 |
Approved assets (12)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Meningococcal C Conjugate Vaccine | 3 |
| Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo) | 3 |
| Egg-derived Influenza Vaccine | 1 |
| Purified Chick Embryo Cell Inactivated Rabies Vaccine | 1 |
| Emulsion, Cell Culture-based, influenza HA vaccine H1N1 | 1 |
Showing 5 of 12 approved assets.
Journals published in (48)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Vaccine | 44 |
| The Pediatric infectious disease journal | 18 |
| Human vaccines & immunotherapeutics | 17 |
| Clinical and vaccine immunology : CVI | 7 |
| Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 7 |
Showing 5 of 48 journals.
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| IPPOX Foundation | Co sponsors trial with | 1 |
| Barbara Ensoli, MD | Co sponsors trial with | 1 |
Latest dated events (234)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2016-06-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2015-08-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2015-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2014-11-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2014-11 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 234 events.
Biomarker capability evidence (35)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| FAS | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FAS | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FASN | Trial sponsor | Primary endpoint in a Phase 3 trial |
| FASN | Trial sponsor | Primary endpoint in a Phase 3 trial |
Showing 5 of 35 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.